UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 155 filers reported holding UNIQURE NV in Q2 2021. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,567,440 | -47.7% | 382,629 | -10.7% | 0.02% | -52.4% |
| Q2 2023 | $4,910,046 | +6.5% | 428,451 | +87.1% | 0.04% | -4.5% |
| Q1 2023 | $4,611,838 | +267.5% | 228,989 | +240.1% | 0.04% | +266.7% |
| Q2 2022 | $1,255,000 | +30.6% | 67,332 | +26.6% | 0.01% | +33.3% |
| Q1 2022 | $961,000 | -14.3% | 53,201 | -1.6% | 0.01% | -10.0% |
| Q4 2021 | $1,121,000 | -16.4% | 54,071 | +29.1% | 0.01% | -28.6% |
| Q3 2021 | $1,341,000 | -43.8% | 41,889 | -40.8% | 0.01% | -51.7% |
| Q1 2021 | $2,385,000 | +74.6% | 70,788 | +87.3% | 0.03% | +61.1% |
| Q4 2020 | $1,366,000 | +105.7% | 37,804 | +109.7% | 0.02% | +38.5% |
| Q3 2020 | $664,000 | -37.1% | 18,029 | -23.0% | 0.01% | -7.1% |
| Q2 2020 | $1,056,000 | -52.1% | 23,400 | -24.0% | 0.01% | -74.1% |
| Q4 2019 | $2,206,000 | +281.7% | 30,779 | +315.9% | 0.05% | +170.0% |
| Q2 2019 | $578,000 | – | 7,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |